目的 分析評價童康片單用及聯(lián)合化學藥治療兒童反復呼吸道感染的臨床療效及安全性。方法 使用計算機對中英文數(shù)據(jù)庫，包括中國學術期刊全文數(shù)據(jù)庫（CNKI）、維普中文期刊全文數(shù)據(jù)庫（VIP）、萬方數(shù)據(jù)庫（Wanfang Data）、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）、Cochrane Library、PubMed和Web of Science進行文獻檢索，收集各數(shù)據(jù)庫建庫起至2022年12月2日童康片單用及聯(lián)合化學藥治療兒童反復呼吸道感染的臨床隨機對照試驗（RCT），使用RevMan 5.4軟件進行Meta分析。結果 共納入13項RCTs、包括1 411例患兒。Meta分析結果顯示：試驗組總有效率高于對照組［RR＝1.25，95% CI（1.19，1.31），P＜0.000 01］，且童康片單用及聯(lián)合化學藥的差異沒有統(tǒng)計學意義；治療后兩組免疫球蛋白IgA［MD＝-0.05，95% CI（-0.48，0.37），P＝0.80］、IgG［MD＝-0.16，95% CI（-0.95，0.62），P＝0.68］、IgM［MD＝0.02，95% CI（-0.32，0.37），P＝0.90］、不良反應率［RR＝0.80，95% CI（0.23，2.80），P＝0.73］比較，差異無統(tǒng)計學意義。結論 童康片可提高治療兒童反復呼吸道感染的療效，且單用或聯(lián)合化學藥對其有效率影響不大，對IgA、IgG、IgM及不良反應發(fā)生情況沒有明顯影響。

Objective To analyze and evaluate the clinical efficacy and safety of Tongkang Tablets alone and in combination with chemical drugs in the treatment of recurrent respiratory tract infections in children. Methods Data were electronically searched from CNKI, CBM, VIP, Wanfang Database, Cochrane Library, PubMed and Web of Science, from the date of establishment to December 2, 2022, for the randomized controlled trial (RCT) of Tongkang Tablets alone and in combination with chemical drugs in the treatment of recurrent respiratory tract infections in children, and analyzed the data using RevMan 5.4 software. Results A total of 13 RCTs involving 1 411 children were included. The Meta-analysis results showed that the total effective rate of the experimental group was higher than that of the control group [RR = 1.25, 95%CI (1.19, 1.31), P< 0.000 01], and the difference between Tongkang Tablets alone and combined chemical drugs was not statistically significant. After treatment, the two groups of immunoglobulins IgA [MD = -0.05, 95%CI (-0.48, 0.37), P= 0.80], IgG [MD = -0.16, 95%CI (-0.95, 0.62), P= 0.68], IgM [MD = 0.02, 95%CI (-0.32, 0.37), P= 0.90], adverse reaction rate [RR = 0.80, 95%CI (0.23, 2.80), P= 0.73] were compared, the difference was not statistically significant. Conclusion Tongkang Tablets can improve the efficacy of treating recurrent respiratory tract infections in children, and the efficacy of single or combined chemical drugs has little effect, and there is no significant effect on the occurrence of IgA, IgG, IgM and adverse reactions.

R287.5;R969.3

國家自然科學青年基金資助項目（82004422）